Mesh.i
Exploration
Accueil
Racine
Exploration
Accueil
Racine

La maladie de Parkinson au Canada (serveur d'exploration) - Exploration (Accueil)

Index « Mesh.i » - entrée « Catechols »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Catecholamines < Catechols < Cathepsin L  Facettes :

List of bibliographic references indexed by Catechols

Number of relevant bibliographic references: 11.
Ident.Authors (with country if any)Title
001C52 (2010) A. Jon Stoessl [Canada]Continuous dopaminergic therapy in Parkinson disease: Time to stride back?
001D75 (2009) Waqas Khan [Canada] ; Sughra Naz ; Abdul Qayyum RanaShortness of breath, a 'wearing-off' symptom in Parkinson's disease.
002169 (2008) M. Jog [Canada] ; M. Panisset ; O. Suchowersky ; B. Réhel ; R. SchecterNaturalistic evaluation of entacapone in patients with signs and symptoms of L-dopa wearing-off .
002703 (2006) R B Postuma [Canada] ; A J Espay ; C. Zadikoff ; O. Suchowersky ; W R W. Martin ; A-L Lafontaine ; R. Ranawaya ; R. Camicioli ; A E LangVitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.
002916 (2006) Jon Doan [Canada] ; Ian Q. Whishaw [Canada] ; Sergio M. Pellis [Canada] ; Oksana Suchowersky [Canada] ; Lesley A. Brown [Canada]Motor deficits in parkinsonian reaching : Dopa-sensitivity influenced by real-world task constraint
002B95 (2004) Hyman M. Schipper [Canada]Brain iron deposition and the free radical-mitochondrial theory of ageing.
002D59 (2003) D. Coyle [Canada] ; M. Barbeau ; M. Guttman ; J-F BaladiThe economic evaluation of pharmacotherapies for Parkinson's disease.
003372 (2000) L. McauleyEntacapone: adjunctive use in patients with advanced Parkinson's disease.
003378 (2000) P. Watkins [États-Unis]COMT inhibitors and liver toxicity.
003836 (1999) J. Rivest [Canada] ; C. L. Barclay [Canada] ; O. Suchowersky [Canada]COMT inhibitors in Parkinson's disease
004430 (1993) M. Guttman [Canada] ; G. Léger [Canada] ; A. Reches [Israël] ; A. Evans [Canada] ; H. Kuwabara [Canada] ; J. M. Cedarbaum [États-Unis] ; J. M. Gjedde [Canada]Administration of the new COMT inhibitor OR‐611 increases striatal uptake of fluorodopa

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Mesh.i -k "Catechols" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Mesh.i  \
                -Sk "Catechols" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Mesh.i
   |clé=    Catechols
}}
Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022